Long-term lamivudine therapy is not reasonable for HBV-associated nephropathy [17]

Nephrology Dialysis Transplantation

Volumn 21, Issue 6, 2006, Pages 1740-1741

  Lai, Ming Yu ^a,b   Yang, Wu Chang ^a,b   Lee, Shon Dong ^a,b   Ng, Yee Yung ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LAMIVUDINE;

DISEASE EXACERBATION; DRUG WITHDRAWAL; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LETTER; LONG TERM CARE; NEPHROSIS; NONHUMAN; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; VIRUS MUTATION;

DRUG RESISTANCE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; NEPHROSIS; RECURRENCE; TIME FACTORS;

EID: 33744826289     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfk001     Document Type: Letter

References (5)

1. Izzedine H, Massard J, Poynard T, Deray G. Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant 2005; Advance access date 1st Nov 2005
2. Chayama K, Suzuki Y, Kobayashi M et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998; 27: 1711-1717
3. Lok AS, Lai CL, Leung N et al. Long term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125: 1714-1722
4. Tang S, Lai FMM, Lui YH et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68: 1750-1758
5. Shibolet O, Ilan Y, Gillis S et al. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396